300,000+ clinical trials. Find the right one.

87 active trials for Soft Tissue Sarcoma

PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS

This study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or metastatic soft tissue sarcoma (STS).

Start: April 2015

Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

The objective of this trial is to assess the safety and tolerability of combining compound 451238 and radiotherapy, treating advanced STS.

Start: November 2018

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of the drug will also be studied.

Start: June 2017

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety of PD-1 monoclonal antibody SHR-1210 and apatinib, at the same time, peripheral circulating blood tumor cells (CTC) detection and CTC-based PD-L1 antibody immunofluorescence detection will be performed.

Start: January 2019

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

To observe the efficacy of apatinib combined with AI regimen chemotherapy compared with AI regimen chemotherapy and single-agent apatinib in patients with unresectable soft tissue sarcoma. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rates (ORR, CR+PR), disease control rate (DCR, CR+PR+SD), and overall survival ( OS). To observe the safety of apatinib combined with AI chemotherapy.

Start: June 2019

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

The study is aimed at evaluating the safety of L19TNF in combination with the most appropriate dose of doxorubicin.

Start: September 2019

CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Start: June 2018